Find participating medical centers and current study status in each of them

    Find participating medical centers

    A study evaluating the efficacy and safety of neoadjuvant treatment with atezolizumab or placebo in combination with platinum-based chemotherapy in patients with resectable stage II, IIIA, or select IIIB non-small cell lung cancer

    A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

    • Cancer
    • Lung Cancer
    • Non-Small Cell Lung Cancer (NSCLC)

    Basic Details

    Gender
    All
    Age
    ≥ 18 Years
    Healthy Volunteers
    No
    Sponsor Hoffmann-La Roche
    Phase Phase 3
    Study Identifier NCT03456063, GO40241, 2023-504209-35-00

     

    How does the IMpower030 clinical trial work?
    This clinical trial is recruiting people who have a specific type of lung cancer called ‘non-small cell lung cancer’ or NSCLC. This includes two types of lung cancer, which your doctor may refer to as adenocarcinoma and squamous cell carcinoma.

    How do I take part in this clinical trial?
    To be able to take part in this clinical trial, you must not have had any prior history of lung cancer or any previous treatment for your current cancer, other than pain medication.

    If you think this clinical trial may be suitable for you and would like to take part, please talk to your doctor.

    If your doctor thinks that you might be able to take part in this clinical trial, he/she may refer you to the closest clinical trial doctor who will give you all the information you need to make your decision about taking part in the clinical trial. You will also find the clinical trial locations at the top of this page.

    You will have some further tests, which may include taking a tumour sample (or this may have already been taken from the first operation), blood tests and physical examinations, to make sure that you will be able to safely take the treatments given in this clinical trial. Some of these tests and procedures may be part of your regular medical care and may be done even if you do not take part in the clinical trial. If you have had some of the tests recently, they may not need to be done again.

    Before starting the clinical trial, you will be told about any risks and benefits of taking part in the trial and what other treatments are available so that you may decide if you still want to take part.

    If you agree to take part in this clinical trial, and your doctor confirms the stage of your cancer and that it can be removed with surgery, then you may be able to be given treatment for your lung cancer.

    What treatment will I be given if I join this clinical trial?
    Everyone who joins the clinical trial will be split into two groups randomly (like flipping a coin) and given one of two different treatments.

    This is a ‘placebo-controlled’ clinical trial, which means that one of the groups will be given an injection into your vein containing no active drug (also known as a ‘placebo’). A placebo is used to show that the doctor or the patients do not sway the results of the clinical trial.

    • Either you will be given the new drug, atezolizumab, and chemotherapy into your vein (this is called an ‘intravenous infusion’) once every 3 weeks for 4 treatment cycles.
    • Or you will be given chemotherapy into your vein and the placebo treatment instead of atezolizumab once every 3 weeks for 4 treatment cycles.

    How often will I be seen in follow-up appointments, and for how long?
    Whichever treatment you are given, you will have surgery to remove your cancer.

    After surgery, if you have been given atezolizumab, you will be given 16 rounds of treatment with atezolizumab once every 3 weeks (without the chemotherapy).

    If you were not given atezolizumab before surgery (meaning you were given placebo treatment) you will be given other care that will help relieve the symptoms caused by your treatment, surgery or cancer and your doctor(s) will meet with you every 6 weeks after your surgery for a year to assess your well-being and recovery.

    A year after your surgery, you will need to meet with your doctor periodically for about 6.5 years to ensure your disease has not returned.

    The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

    The information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

    Results Disclaimer

    What you can do next

    Save the study number

    To find this study again later, copy and save the study number:

    {{ctId}}

    Talk to a doctor or nurse

    Talk to a doctor or nurse

    To see if this study is a good fit, talk to your doctor or nurse you trust.

    Together, you can look at the For Medical Professional tab and look into your medical history.

    Reach out for more info

    Some medical centers in this study offer a contact line. Click "Find participating medical centers" in the map below.

    Find participating medical centers and current study status in each of them

      Find participating medical centers

      About Clinical Trials

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Roche conduct clinical trials?